1548 — Genscript Biotech Income Statement
0.000.00%
- HK$17.68bn
- HK$10.99bn
- $839.53m
Annual income statement for Genscript Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 273 | 391 | 490 | 626 | 840 |
Cost of Revenue | |||||
Gross Profit | 180 | 256 | 283 | 304 | 410 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 386 | 667 | 1,005 | 1,044 | 1,163 |
Operating Profit | -113 | -276 | -515 | -418 | -323 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -114 | -282 | -517 | -432 | -351 |
Provision for Income Taxes | |||||
Net Income After Taxes | -118 | -281 | -518 | -428 | -355 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -96.9 | -205 | -359 | -227 | -95.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -96.9 | -205 | -359 | -227 | -95.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.052 | -0.106 | -0.175 | -0.104 | -0.041 |